Blog
CMC Pharma Solutions
Canè S.p.A. and CMC PHARMA SOLUTIONS CORP. will participate with a stand at the 31st Interamerican Congress of Cardiology.
On June 5, 6 and 7, the world of Cardiology will set its eyes on the Americas. Specifically, in the 31st edition of the Interamerican Congress of Cardiology, a meeting organized by the Interamerican Society of Cardiology -SIAC, which will be packed with news,...
CMC Pharma Solutions organizes the visit of renowned Colombian doctors to the CANÈ MEDICAL TECHNOLOGY facilities
Doctors: Alejandro LondoñoInternist Pulmonologist, Coordinator of the Lung Transplant Program, member of the management groups of patients with Pulmonary Hypertension and patients with Pulmonary Fibrosis, Clínica Cardio VID, Medellinand Rafael CondeInternist...
8º CURSO INTERNACIONAL de CIRCULACIÓN PULMONAR “Dr. Abel Ayerza”
CMC PHARMA SOLUTIONS and CANÈ MEDICAL TECHNOLOGY exhibit some of the CRONO series ambulatory infusion pumps available in Argentina, as part of the 8º CURSO INTERNACIONAL de CIRCULACIÓN PULMONAR “Dr. Abel Ayerza”…
CMC Pharma Solutions promotes the visit of Canè Directors to reference medical centers in Buenos Aires
Mr. Paolo Canè and Mr. Claudio Canè, Managing Directors of CANÈ MEDICAL TECHNOLOGY, visited the hospital of the Centro Gallego de Buenos Aires.They have been received by Dr. Adrían Lescano and his team. Mr. Paolo Canè and Mr. Claudio Canè with Dr. Adrían Lescano and...
CMC Pharma Solutions organizes the visit of Argentine Opinion Leaders to the Canè Medical Tecnology facilities
Doctors Guillermo Bortman, David Peña and Sergio Perrone, leaders in Argentina and Latin America in the treatment of pulmonary arterial hypertension, visited the CANÈ facilities in Rivoli (Italy). They were received by Messrs. Paolo Canè and Claudio Canè, Managing...
INVIMA has just granted a Marketing Authorization to the CRONO SC ambulatory infusion pump of Canè Medical Technology
CMC Pharma Solutions and its distributor in Colombia, Pyxis Pharmaceutical, are thrilled to announce that the Instituto Nacional de Vigilancia de Medicamentos y Alimentos de Colombia - INVIMA has just granted a Marketing Authorization to the CRONO SC...
CRONO SC portable pump
CRONO SC portable pump was successfully tested for Treprostinil infusion, obtaining an indication for use in pulmonary arterial hypertension (PAH) in addition to palliative care. The possibility of selecting reduced partial volumes compatible with the amount of drug...
CRONO PAR4 20 ambulatory infusion pump
CRONO PAR4 20 is an ambulatory infusion pump, designed for the subcutaneous infusion of apomorphine in the treatment of Parkinson’s disease, which uses specific 10 ml and 20 ml syringes called reservoirs. Main technical features of the pump: The...
CRONO ambulatory infusion pump
The CRONO infusion pump is designed for subcutaneous infusions in iron chelation therapy and uses dedicated 10 and 20 ml syringes. The feed mechanism, which acts directly on the rubber piston of the reservoir, enables the pump to achieve a high thrust force...
CRONO S-PID4 100 ambulatory infusion pump
CRONO S-PID4 100 is an ambulatory infusion pump, designed for the subcutaneous administration of immunoglobulins, which uses specific 100 ml syringes called réservoirs. Main technical features of the pump: The possibility of choosing from three...
Distributor of Canè S.p.A. infusion systems and accessories
CMC Pharma Solutions distributes in Latin America Canè S.p.A. infusions systems and accessories. For more information on the availability in Latin America of the CRONO ambulatory infusion pumps from Canè S.p.A., the dedicated CRONO CRN syringes and the CRONO JET...
Signature of an agreement between CMC Pharma Solutions and CHEMTEST Argentina
Both companies have just signed a Product Registration Services Agreement, with the aim of achieving the CE mark for the in vitro diagnostic medical device ELA CHEMSTRIP COVID-19. The elaboration of the Technical File to be presented in the certification and...
The treatment of patients with Primary Immunodeficiency disorders (PID)
Patients with PID disorders are born without some of the body’s immune defenses or with an immune system that is not working properly. These people suffer more frequent, longer lasting or difficult to treat infections than the infections suffered by people with a...
Signature of a Guidance and strategic Support agreement between AIO Health Pro and Dermclar
Both companies have just signed a Guidance and strategic Support agreement for the launch in Spain of the Dermclar Professional and Personal Care lines. The agreement has been made possible thanks to the intermediation of CMC Pharma Solutions. The signed...
Parkinson’s disease: a pathology in constant progression
Parkinson's, a long-term degenerative and progressive disorder of the central nervous system, affects one in 100 people over 60 years of age. Currently, there are about 6.3 million people with this disease in the world and WHO predicts that, by 2030, they will become...
Omnichannel digital strategy to drive prescription and sell out
Within the framework of the Representation Agreement signed with AIO HEALTH PRO, CMC Pharma Solutions has the privilege of proposing to Latin American pharma companies the use of the first and only medical communication platform, offering innovative remote solutions...
Signature of a Partnership Agreement
CMC Pharma Solutions Corp., a consulting firm headquartered in Miami with offices in Barcelona and Buenos Aires, is pleased to announce an enterprise partnership with the Barcelona based Gabinete Técnico Farmacéutico M.Camps, with proven expertise in European...
The Spanish pharmaceutical sector analyzes future cooperation with the United Kingdom
La embajada británica en Madrid y Farmaindustria, junto con ICEX y el Ministerio de Industria, Comercio y Turismo, organizaron una sesión de trabajo en Madrid para las empresas del sector farmacéutico en la que se revisaron las directrices para asegurar la...
The European Commission approves Bavencio in combination with axitinib for advanced renal cell carcinoma
La aprobación de la UE se basa en los resultados del ensayo JAVELIN Renal 101 que demuestran una mejora significativa en la supervivencia libre de progresión con avelumab en combinación con axitinib, en comparación con sunitinib. Esta aprobación se aplica a todos los...